The Treatment of Growth Hormone Deficiency in Adults

Bengt-Åke Bengtsson and Gudmundur Johannsson

Research Center for Endocrinology and Metabolism Sahlgrenska University Hospital Sahlgrenska, S-413 45 Göteborg, Sweden


    Introduction
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 
ADULT GH deficiency is recognized as a specific clinical syndrome (1). Well-controlled clinical studies have shown that GH deficiency in adults is associated with a cluster of cardiovascular risk factors (2). These patients have an increased amount of body fat with an abdominal preponderance (3, 4), an increased prevalence of hypertension (5), impaired fibrinolysis (4), glucose intolerance (6), insulin resistance (7), and premature atherosclerosis (6). This cluster of cardiovascular risk factors associated with GH deficiency might explain the doubling in cardiovascular mortality observed in hypopituitary patients (8, 9). The quality of life is impaired, and there are data suggesting an increased prevalence of disability pensions among these patients (10, 11). In addition, these patients have reduced bone mineral content and density with increased prevalence of fractures (12, 13). Randomized placebo-controlled studies indicate that GH replacement therapy can reverse several of these biological changes (3, 14, 15, 16, 17, 18). Although these studies have been of relatively short duration, replacement therapy with GH in adults has now been approved by the regulatory authorities in Europe and the United States. The long-term experience is, however, limited.

The optimum goal for GH replacement in adults is to improve and normalize the aberrations associated with adult GH deficiency. One cornerstone in releasing this objective is well-defined normative values for the efficacy measurements that are used, particularly during more prolonged GH treatment when dose adjustment may be needed because of increasing age. No golden standard for the monitoring of GH treatment is available, as a specific marker of its tissue effect is lacking.

Previous treatment trials in adult patients with GH deficiency have used doses of GH based on body weight or body surface area, adopted essentially from the experience of treating GH-deficient children, and have, therefore, ignored the presence of an individual responsiveness to GH (19). Some of these trials have reported a high frequency of side effects, mainly associated with fluid retention (3, 17). These side effects were more prone to occur in older patients, and in patients with a higher body mass index (20, 21), and may explain why trials comprising young and mostly lean adults have reported few or no side effects (14, 22).


    GH secretion in adults
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 
In healthy adults, it is known that fertile women have a higher GH secretion than young men (23) and that GH secretion is inversely associated with increasing age and adiposity (24, 25). These factors should be considered during GH replacement. Instead, GH dose schedules based on body weight or surface area results in higher daily doses of GH in subjects with higher body weight and lower for most women compared with men.

In middle-aged women, the reported daily production of GH is about 47 µg/L x 24 h, whereas the mean production in the adult male is 15 µg/L x 24 h. Assuming an availability of sc administered recombinant human GH of 60%, a dose between 0.3–0.6 mg (0.6–1.8 IU) per day should be in agreement with the physiological GH production in adults (26), which is markedly lower than the doses of GH used in previous trials of GH replacement in adults.


    Individual responsiveness
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 
A highly variable response to GH treatment in adult GH deficiency has recently been documented. The variability was, to some extent, explained by differences in baseline body mass index (BMI), baseline serum levels of the GH binding protein (GHBP), age, and gender. In response to GH treatment, patients with a high BMI experienced a lower reduction in body fat and patients with low baseline levels of GHBP and younger patients displayed the most marked increase in lean body mass and lean to fat ratio (19).

An inverse relationship between the baseline concentration of GHBP and changes in body composition in response to GH treatment is in contrast to previous experiences in children (27), where the baseline level of GHBP correlates positively with the response to GH administration in terms of growth velocity and insulin-like growth factor (IGF) I increment. The observation is, however, in line with in vitro experiments that demonstrate a dampening effect by GHBP on the binding of GH to cells and on the GH-dependent IGF-I production (28, 29).

A gender difference in the response to GH treatment has been observed. The increase in fat-free mass, total body water, and decrease in body fat is more marked in men than in women (19, 30). In addition, men increase their lipoprotein (Lp) (a) levels more than women (31), and women demonstrate a more marked increase in total bone mineral density and a less pronounced increment in bone formation and bone resorptions markers than men in response to the GH treatment (32). This gender difference is most probably explained by differences in interaction between GH and estrogens and androgens, respectively.

Adult GH deficiency is not a single clinical entity because the onset may occur during childhood (CO) or in adult life (AO). GH deficiency occurring in children is mainly idiopathic and is recognized as growth failure. Appropriate therapy with GH, standardized over the past decade, is discontinued when final height is reached. Somatic development is unlikely to be complete at this stage. Thus, height, body weight, BMI, lean body mass, and waist to hip ratio were found to be higher in AO than in CO GH-deficient patients. Serum IGF-I concentration was lower in CO than in AO GH-deficient patients (19, 33). Both groups displayed significant psychosocial distress, but the deviation from normality was greater in AO patients (33). The apparent differences in body composition at baseline between subjects with AO and CO GH deficiency is probably explained by the lower body height in CO (19). Other consequences of GH deficiency have been suggested to be more pronounced in adults with CO, particularly in terms of heart structure and function (34, 35), muscle mass (14, 36), and bone mass (12, 37). This may be an effect of the immediate discontinuation of GH treatment after the final height is reached (38). Whether this per se makes the CO patients more or less responsiveness to GH is not known (19).


    Markers of GH action
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 
There is no optimal marker for long-term physiological replacement dose of GH. It is unlikely that GH treatment can be adequately monitored by clinical means alone. Hence, various GH-dependent biochemical markers have been suggested, such as IGF-I. IGFs circulate bound to specific binding proteins [IGF binding proteins (IFGBPs)], which regulate their bioavailability and bioactivity. To date, six such IGFBPs have been characterized. IGFBP-3 circulates in highest concentrations and binds to 90% of circulating IGFs to form 150-kDa ternary complexes with an acid-labile subunit (ALS) (39). Both IGFBP-3 and ALS levels are GH dependent. In a study of adult men in the age range of 20–40 yr with CO GH deficiency, the minimal dose of GH required for normalization of serum IGF-I concentration was 0.22 mg/m2·day and 0.33 mg/m2·day for ALS and IGFBP-3. In patients receiving 0.67 mg/m2·day, mean serum IGF-I concentration rose to abnormally high levels, whereas at this dose mean serum IGFBP-3 and ALS concentrations were not different from normal. The lower sensitivity of IGFBP-3 and ALS to GH doses in the high range was also apparent during long-term treatment (40). A dose of 0.2, 0.4, or 0.6 mg per day was used in 51 AO GH-deficient patients. In female patients, a dose of 0.2 mg/day was insufficient to normalize serum IGF-I after 12 weeks of treatment, whereas doses of 0.4 and 0.6 mg/day were able to normalize serum IGF-I levels in most female GH-deficient patients. In the male patients, a dose of 0.2 IU/day was in almost all patients sufficient to normalize serum IGF-I levels (41).

Serum IGF-I may, however, be clinically inadequate in reflecting the GH status of the individual patient because a substantial number of patients with severe GH deficiency have normal serum IGF-I concentrations (42, 43). It should also be recognized that GH delivered by a more continuous pattern increases serum IGF-I concentration more than a pulsatile secretion of GH (44), whereas the pulsatile pattern may in some respects produce a more marked tissue response (45). The usefulness of serum IGF-I is further complicated by the fact that there is a diurnal variation during daily sc evening injections of GH, irrespective of whether the patients have been treated for a short or long period of time. A serum sample obtained in the morning from a GH-deficient subject given GH in the evening would overestimate the true 24-h integrated serum concentrations of IGF-I by about 14–17% (46). During more prolonged treatment over 2 yr, increased sensitivity to GH was seen, as the concentration of IGF-I remained unchanged during simultaneous 20% dose reduction of GH (20).

Changes in body composition have been a remarkable consistent finding in all treatment trials with GH in adult GH deficiency. Assessing body composition could, therefore, be a tool for optimizing the replacement dose and to monitor the long-term treatment effects. Bioelectric impedance analysis is a simple technique to assess body water. By applying this method in young adult males with GH deficiency it was found that an average dose of GH of 0.37 mg/m2·day resulted in a rapid normalization of whole body resistance. Doses equal to or higher than 0.67 mg/m2·day resulted in abnormally low resistance, suggesting overhydration (47).

An incongruity between the normalization of serum IGF-I concentration and body composition has been observed. In a 2-yr study, no relationship was found between the changes in serum IGF-I concentration and the changes in body composition (20). Moreover, in that study the initial dose of GH was based on the patient’s body weight, but after dose adjustment due to side effects and serum levels of IGF-I above the age and sex adjusted reference values there was no relationship between the dose of GH and body weight, indicating the importance of factors other than body weight for the daily dose of GH.


    Individualized dose titration
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 
In a study of 60 adult GH-deficient patients an individualized dose schedule was used with a low starting dose (0.17 mg or 0.33 mg per day), independent of body weight. The dose was titrated according to clinical response, age- and sex-adjusted reference values for serum IGF-I, and according to age-, sex-, and body weight-adjusted reference values for body composition. Within a year, the average GH dose was 0.45 mg per day. Compared to a matched group receiving an established GH dose according to body weight (12 µg/kg·day), similar mean response to GH in terms of changes in body composition, glucose homeostasis, Lp(a) and blood pressure was obtained in both treatment groups, with significantly fewer side effects in the group receiving the individualized dose schedule. By using the individualized dose schedule for GH treatment, it was found that women were given more GH per kg of body weight than men and older patients less GH per kg of body weight (48). This is well in accordance with our knowledge about individual responsiveness to GH and physiological GH secretion in healthy adults.

The previously noted incongruity between the normalization of serum IGF-I concentration and body composition was also obvious in this trial (48). Consequently, individualized GH doses enabled one third of the patients to normalize both their serum IGF-I and body composition, but overtreatment was also observed. This demonstrates the large variance and lack of precision of an individual measurement used to monitor GH replacement. Although several disadvantages, the normalization of serum IGF-I concentration is probably the most useful marker of GH treatment (40) and may better reflect overtreatment than other serum markers and the measurement of body composition.

It has been suggested that lower doses/levels of IGF-I stimulate bone formation more markedly than bone resorption (49). Furthermore, IGF-I may be more potent in enhancing the formation of collagen type I and less effective when it comes to stimulating bone resorption than GH (50). It has, therefore, been suggested that lower doses of GH may generate a more marked anabolic action on bone than higher doses of GH (51). The results of measurements of serum osteocalcin and total body bone mineral content in the trial comparing individualized GH doses with higher doses based on body weight (48) indicate, however, that the anabolic action on bone is no less with higher doses of GH than with lower doses. Different baseline bone mineral density z-scores should, however, be considered when studying the response to GH treatment in terms of bone mineral content and bone mineral density (32).

The increased Lp(a) concentration in response to GH might be an effect of overly high doses of GH (31, 52). However, although a lower, individualized and probably more physiologic amount of GH is administered, the increment in Lp(a) is similar to that in patients with higher doses of GH (48). This suggests that the more continuous bell-shaped pattern of GH during sc administration might be of more importance to the increment in Lp(a) than the total amount of GH administered (53). We know little about the importance of the time of GH exposure in terms of responsiveness during more prolonged GH treatment, but these aspects are important when it comes to the aim of achieving a physiologic GH replacement.

The results of a large, long-term study (20–50 months) (54) confirm the findings of previous, shorter investigations showing that GH replacement therapy can significantly improve many aspects of quality of life in adults with GH deficiency (10, 17, 55). In addition, the improvements in quality of life that occur shortly after the initiation of GH therapy are sustained in the longer term. Indeed, it seems that some aspects of quality of life continue to improve during long-term therapy. Furthermore, in a retrospective analysis, almost 60% of the patients receiving GH for 12–68 months felt that their quality of life was still improving. An important finding is that almost one third of patients who experience beneficial effects of GH therapy state that such effects have become noticeable only after GH had been administered for at least 6 months. This finding has clear implications for clinical practice: it indicates that, once the decision has been taken to initiate GH therapy in an adult with GH deficiency, the therapy should be continued for a minimum of 6 months, and ideally, for longer before judgments are made regarding its efficacy in improving quality of life and psychological well-being.

In the absence of an optimal marker for physiological replacement therapy of GH in adults the importance of clinical judgment is increased. To avoid side effects in the initial phase of treatment, the value of closely monitoring clinical effects, particular in terms of increased extracellular fluid volume becomes evident. This is because normalization of serum levels of IGF-I does not exclude the possibility that the GH dose is too high in an individual patient (40). Furthermore, as stated previously, the delay until the patient clearly experiences benefits of the treatment may be long. The patient should be carefully informed of this and that should be considered during the more prolonged GH replacement therapy in adults.


    Safety
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 
Concern has been expressed about the potential risk of development of neoplasia during GH replacement therapy. This is based in part on the increased risk of neoplasia in acromegalic patient. However, experience from a long-term surveillance study in pediatric patients (56, 57) does not show any increased risk of new or recurrent neoplasia. However, it should be borne in mind, that in contrast to the situation in children, GH deficiency in adults is predominantly secondary to pituitary and peripituitary tumors and their associated therapy.

An increased left ventricular wall thickness was observed after 42 months of GH treatment in a small number of patients. These patients received overly high doses of GH, at least during the initial phase of treatment (58). This indicates that the therapeutic window with GH in terms of heart structure and function is probably not as wide as has been thought, particularly during long-term replacement, as changes in the myocardium may progress with prolonged GH administration. However, direct extrapolation of data from acromegalic patients to GH-deficient patients with GH therapy seems inappropriate, as the production rate of GH in acromegaly by far exceeds the ordinary GH replacement dose. Further long-term monitoring of GH-deficient adults receiving GH substitution therapy is clearly needed.


    Summary
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 
In analogy with other hormonal replacement therapy GH treatment should be commenced with a low starting dose, independent of body weight or body surface area. Hormonal replacement should mimic the normal physiology to minimize the risk of side effects in the life-long replacement of adults. We should, therefore, consider individual responsiveness and also be aware of the difference between pattern of GH under normal condition and during sc administration. The safety and monitoring of GH replacement therapy in adults have been addressed in the Growth Hormone Research Society Consensus Guidelines for Diagnosis and Treatment of Adults with GH Deficiency from the Port Stephens Workshop, April 1997 (59). Besides finding better and more accurate biochemical markers for choosing correct GH replacement dose, future research should address the long-term benefits and safety with GH replacement in adults, with special emphasize on incipient risks in terms of cardiovascular disease (31, 58) and of neoplasia, in particular.


    References
 Top
 Introduction
 GH secretion in adults
 Individual responsiveness
 Markers of GH action
 Individualized dose titration
 Safety
 Summary
 References
 

  1. Cuneo RC, Salomon F, McGauley GA, Sönksen PH. 1992 The growth hormone deficiency syndrome in adults. Clin Endocrinol. 37:387–397.[Medline]
  2. Bengtsson B-Å, Rosén T, Johansson J-O, Johannsson G, Oscarsson J, Landin-Wilhelmsen K. 1995 Cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab. 2(Suppl B):29–35.
  3. Salomon F, Cuneo RC, Hesp R, Sönksen PH. 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 321:1797–1803.[Abstract]
  4. Johansson J-O, Landin K, Tengborn L, Rosén T, Bengtsson B-Å. 1994 High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb Vasc Biol. 14:434–437.[Abstract]
  5. Rosén T, Edén S, Larsson G, Wilhelmsen L, Bengtsson B-Å. 1993 Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. 129:195–200.[Medline]
  6. Markussis V, Beshyam SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. 1992 Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 340:1188–1192.[Medline]
  7. Johansson J-O, Fowelin J, Landin K, Lager I, Bengtsson B-Å. 1995 Growth hormone-deficient adults are insulin-resistant. Metabolism. 44:1126–1129.[Medline]
  8. Rosén T, Bengtsson B-Å. 1990 Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet. 336:285–288.[Medline]
  9. Bülow B, Hagmar L, Mikozy Z, Nordström C-H, Erfurth EM. 1996 Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol. 46:75–81.[CrossRef]
  10. McGauley GA, Cuneo RC, Salomon F, Sönksen PH. 1990 Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res. 33(Suppl 4):52–54.
  11. Rosén T, Wirén L, Wilhelmsen L, Wiklund I, Bengtsson B-Å. 1994 Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol. 40:111–116.[Medline]
  12. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M. 1992 Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab. 74:118–123.[Abstract]
  13. Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson B-Å. 1997 Increased fracture rate in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 137:240–245.[Medline]
  14. Jørgensen JOL, Pedersen SA, Thuesen L, et al. 1989 Beneficial effect of growth hormone treatment in GH-deficient adults. Lancet. i:1221–1225.
  15. Binnerts A, Swart GR, Wilsson JHP, et al. 1992 The effects of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol. 37:79–87.[Medline]
  16. Whitehead H, Boreman C, McIlrath EM, et al. 1992 Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol. 36:45–52.[Medline]
  17. Bengtsson B-Å, Edén S, Lönn L, et al. 1993 Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 76:309–317.[Abstract]
  18. Baum HB, Biller BMK, Finkelstein JS, et al. 1996 Effects of physiological growth-hormone therapy on bone-density and body-composition in patients with adult-onset growth-hormone deficiency—a randomized, placebo-controlled trial. Ann Intern Med. 125:883–890.[Abstract/Free Full Text]
  19. Johannsson G, Bjarnason R, Bramnert M, et al. 1996 The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH binding protein, body mass index, age and gender. J Clin Endocrinol Metab. 81:1575–1581.[Abstract]
  20. Johannsson G, Rosén T, Lindstedt G, Bosaeus I, Bengtsson B-Å. 1996 Effects of 2 years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab. 3(Suppl A):3–12.
  21. Holmes SJ, Shalet SM. 1995 Which adults develop side-effects of growth hormone replacement? Clin Endocrinol. 43:143–149.[Medline]
  22. Amato G, Carella C, Fazio S, et al. 1993 Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab. 77:1671–1676.[Abstract]
  23. Ho KKY, Evans WS, Blizzard RM, et al. 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man. Importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 64:51–58.[Abstract]
  24. Rudman D, Kutner MH, Rogers CM, Lubin MF, Flemming GA, Bain RP. 1981 Impaired growth hormone secretion in the adult population. Relation to age and adiposity. J Clin Invest. 67:1361–1369.[Medline]
  25. Iranmanesh A, Lizarralde G, Veldhuis JD. 1991 Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 73:1081–1088.[Abstract]
  26. Van den Berg G, Veldhuis JD, Frölich M, Roelfsema F. 1996 An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentration in men and premenopausal women. J Clin Endocrinol Metab. 81:2460–2467.[Abstract]
  27. Martha Jr PM, Reiter EO, Dávila N, Shaw MA, Holcombe JH, Baumann G. 1992 Serum growth hormone (GH)-binding protein/receptor: an important determinant of GH responsiveness. J Clin Endocrinol Metab. 75:1464–1469.[Abstract]
  28. Mannor DA, Winer LM, Shaw MA, Baumann G. 1991 Plasma growth hormone (GH)-binding proteins: effect on GH binding to receptors and GH action. J Clin Endocrinol Metab. 73:30–34.[Abstract]
  29. Lim L, Spencer SA, McKay P, Waters MJ. 1990 Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. Endocrinology. 127:1287–1291.[Abstract]
  30. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab. 82:550–555.[Abstract/Free Full Text]
  31. Johannsson G, Oscarsson J, Rosén T, et al. 1995 Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults: influence of gender and apo(a) and apoE phenotypes. Arterioscler Thromb Vasc Biol. 15:2142–2150.[Abstract/Free Full Text]
  32. Johannsson G, Rosén T, Bosaeus I, Sjöström L, Bengtsson B-Å. 1996 Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 81:2865–2873.[Abstract]
  33. Attanasio AF, Lamberts SWJ, Matranga AMC, et al. 1997 Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab. 82:82–88.[Abstract/Free Full Text]
  34. Cittadini A, Cuocolo A, Merola B, et al. 1994 Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol. 267:E219–E225.
  35. Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I. 1995 Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. J Clin Endocrinol Metab. 80:659–666.[Abstract]
  36. Cuneo RC, Salomon F, Wiles CM, Sönksen PH. 1990 Skeletal muscle performance in adults with growth hormone deficiency. Horm Res. 33(Suppl 4):55–60.
  37. Rosén T, Hansson T, Granhed H, Szücs J, Bengtsson B-Å. 1993 Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. 129:201–208.[Medline]
  38. Saggese G, Baroncelli GI, Bertelloni S, Barsanti S. 1996 The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab. 81:3077–3083.[Abstract]
  39. Baxter RC, Martin JL. 1994 Structure of the M 140,000 growth hormone dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA. 86:6898–6902.
  40. De Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, Van der Veen E. 1996 Monitoring of growth hormone replacement therapy in adults, based on measurements of serum markers. J Clin Endocrinol Metab. 81:1371–1377.[Abstract]
  41. Janssen YJH, Frölich M, Roelfsema F. 1997 A low starting dose of Genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab. 82:129–135.[Abstract/Free Full Text]
  42. Svensson J, Johannsson G, Bengtsson B-Å. 1997 Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clin Endocrinol. 46:579–586.[CrossRef][Medline]
  43. Hoffman DM, O’Sullivan AJ, Baxter RC, Ho KKY. 1994 Diagnosis of growth hormone deficiency in adults. Lancet. 343:1064–1068.[Medline]
  44. Johansson J-O, Oscarsson J, Bjarnason R, Bengtsson B-Å. 1996 Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis. Metabolism. 45:362–369.[Medline]
  45. Isgaard J, Carlsson L, Isaksson OGP, Jansson J-O. 1988 Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology. 123:2605–2610.[Abstract]
  46. Oscarsson J, Johannsson G, Johansson J-O, Lundberg P-A, Lindstedt G, Bengtsson B-Å. 1997 Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults. Clin Endocrinol. 46:63–68.[Medline]
  47. De Boer H, Blok GJ, Voerman B, De Vries P, Popp-Snijders C, Van der Veen E. 1995 The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. J Clin Endocrinol Metab. 80:2069–2076.[Abstract]
  48. Johannsson G, Rosén T, Bengtsson B-Å. 1997 Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol. 47:571–581.[Medline]
  49. Ghiron LJ, Thompson JL, Holloway L, et al. 1995 Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res. 10:1844–1852.[Medline]
  50. Johansson AG, Lindh E, Blum WF, Kollerup G, Søorensen OH, Ljunghall S. 1996 Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 81:44–48.[Abstract]
  51. Amato G, Izzo G, La Montagna G, Bellastella A. 1996 Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol. 45:27–32.[Medline]
  52. Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson B-Å. 1993 Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscl Thromb Vasc Biol. 13:296–301.[Abstract]
  53. Oscarsson J, Ottosson M, Johansson J-O, et al. 1996 Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. Metabolism. 45:370–377.[Medline]
  54. Wirén L, Bengtsson B-Å, Johannsson G. 1997 Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol. In press.
  55. Burman P, Broman JE, Hetta J, et al. 1995 Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab. 80:3585–3590.[Abstract]
  56. Shalet SM. 1993 Leukemia in children treated with growth hormone. J Peadiatr Endocrinol. 6:109–111.
  57. Buchanan CR, Preece MA, Milner RD. 1991 Mortality, neoplasia and Creutzfelt-Jakob disease in patients treated with human pituitary growth hormone in United Kingdom. Br Med J. 302:824–828.[Medline]
  58. Johannsson G, Bengtsson B-Å, Andersson B, Isgaard J, Caidahl K. 1996 Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults: preliminary data from a small group of patients. Clin Endocrinol. 45:305–314.[CrossRef][Medline]
  59. Invited Report of a Workshop. 1998 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on adult growth hormone deficiency. J Clin Endocrinol Metab. 83:379–381.[Abstract/Free Full Text]